nach oben

Wiener klinische Wochenschrift

Erschienen in:

17.12.2020 | review article

Prevalence of neuropathy in patients with type 2 diabetes in Iran

A systematic review and meta-analysis

verfasst von: Dariush Afshari Aliabadi, MD, Nasrin Moradian, MD, Elham Rahmanian, MSc, Masoud Mohammadi, MSc

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 5-6/2021

Einloggen, um Zugang zu erhalten

Summary

Background

Diabetic neuropathy is one of the most common complications of diabetes, which leads to amputation and significant disability in patients. Studies conducted in this field show different prevalences and inconsistencies in the country. This study attempts to determine the overall prevalence of neuropathy in patients with type 2 diabetes in Iran with a meta-analysis.

Methods

The present study was conducted using a meta-analysis method from January 2000 to December 2018. The papers related to the study subject were obtained from searching Scopus, ScienceDirect, Magiran, Barakat Knowledge Network, SID, Medline (PubMed), and Google Scholar databases. The heterogeneity of studies was examined using I² index and the data were analyzed using the software Comprehensive Meta-Analysis (version 3, Biostat, Englewood, NJ, USA).

Results

The results of the systematic review showed regional differences in the prevalence of neuropathy in Iran. According to the meta-analysis and review of 10 studies and 2992 individuals between the ages of 5 years and 86 years, the overall prevalence of neuropathy in type 2 diabetes patients in Iran was 56.5% (95% confidence interval, CI 42.8–69.3%). The highest prevalence of neuropathy in type 2 diabetic patients was found in Mashhad with 87.2% (95% CI 77.9–92.3%) in 2012 and the lowest prevalence of neuropathy in type 2 diabetic patients was found in Ahvaz with 22.7% (95% CI 18.5–27.6%) in 2014. With the increase in years of research, the prevalence of neuropathy in type 2 diabetes in Iran was reduced, with statistically significant differences (P < 0.05).

Conclusion

Considering the high prevalence of neuropathy in patients with type 2 diabetes in the country, it is essential that health policy makers take effective measures to reduce this disease in diabetes patients.

Vorheriger Artikel Silicone soft socket system for the treatment of geriatric transtibial amputees

Nächster Artikel Emergency department overcrowding

Pradeepa R, Mohan V. Prevalence of type 2 diabetes and its complications in India and economic costs to the nation. Eur J Clin Nutr. 2017;71(7):816–24.CrossRef

Khatib O, Tabatabaei Malazy O. Prevention and public approach to diabetic foot. Iran J Diabetes Lipid Disord. 2007;7(2):123–33.

Chen DK, Frizzi KE, Guernsey LS, Ladt K, Mizisin AP, Calcutt NA. Repeated monitoring of corneal nerves by confocal microscopy as an index of peripheralneuropathy in type‑1 diabetic rodents and the effects of topical insulin. J Peripher Nerv Syst. 2013;18(4):306–15.CrossRef

Esteghamati A, Gouya MM, Abbasi M, Delavari A, Alikhani S, Alaedini F, et al. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran: national survey of risk factors for non-communicable diseases of Iran. Diabetes Care. 2008;31(1):96–8.CrossRef

Shaw JE, Sicree PZ, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.CrossRef

Ahmadi A, Hasanzadeh J, Rahimi MM, Lashgari L. Factors affecting the quality of life in patients with type 2 diabetes Chahar Mahal Bakhtiari. J North Khorasan Univ Med Sci. 2011;3(1):7–13.CrossRef

Rahmanian E, Salari N, Mohammadi M, Jalali R. Evaluation of sexual dysfunction and female sexual dysfunction indicators in women with type 2 diabetes: a systematic review and meta-analysis. Diabetol Metab Syndr. 2019;11:73.CrossRef

Mohammadi M, Vaisi Raiegani AA, Jalali R, Ghobadi A, Salari N. The prevalence of retinopathy among type 2 diabetic patients in Iran: a systematic review and meta-analysis. Rev Endocr Metab Disord. 2019;20(1):79–88.CrossRef

Larijani B, Abol Hasani F. Epidemiology of diabetes mellitus in Iran. Iran J Diabetes Lipid Disord. 2001;1(1):1–8.

10.

Booya F, Bandarian F, Larijani B, Pajouhi M, Nooraei M, Lotfi J. Potenzial risk factors for diabetic neuropathy: a case control study. BMC Neurol. 2005;5:24.CrossRef

11.

Hunt D. Using evidence in practice. Foot care in diabetes. Endocrinol Metab Clin North Am. 2002;31:603–11.CrossRef

12.

Kiani J, Moghimbeigi A, Azizkhani H, Kosarifard S. The prevalence and associated risk factors of peripheral diabetic neuropathy in Hamedan, Iran. Arch Iran Med. 2013;16(1):17–9.PubMed

13.

Boulton AJM, Malik RA, Arezz JC, Sosenko JM. Diabetic somatic neuropatheis. Diabetes Care. 2004;27:1458–86.CrossRef

14.

Miralles-García JM, de Pablos-Velasco P, Cabrerizo L, Pérez M, López-Gómez V. Prevalence of distal diabetic polyneuropathy using quantitative sensory methods in a population with diabetes of more than 10 years’ disease duration. Endocrinol Nutr. 2010;57(9):414–20.CrossRef

15.

Abbasian M, Delvarianzadeh M. Evaluation of complications of diabetes in patients referring to diabetes clinic in Shahrood. J Knowl Health. 2007;2(4):17–21.

16.

Mohamadianinejad SE, Shahbazian HB, Kashipazha D, Karimi M, Oghbaei M, Shalilahmadi D, et al. Risk factors associated with diabetic neuropathy in type 2 diabetic patients referred to diabetic clinic of Golestan Hospital, Ahvaz, Iran. Jundishapur Sci Med J. 2013;12(2):141–7.

17.

Khamseh ME, Nakhjavani M, Hossainpanah F, Kalantari S, Sanjari M, Mohammadpeigi M. How to control the metabolic rate and the incidence of diabetes mellitus in patients with type 2 diabetes in Iran. J Payesh. 2013;13(6):705–12.

18.

Kargarian Marvasti S, Abolghasemi J, Heydari I, Rimaz S. Effective factors in the time of development of neuropathy in type II diabetic patients. Iran J Epidemiol. 2017;13(2):80–9.

19.

Khatoni A, Abdi A, Hoseini E, Fattah pour T, Feizi H. Assessment of risk factors and complications of type2 diabetes in patients of Ghasreshirin diabetes center in 2011. Nurs J Vulnerable. 2015;2(2):1–14.

20.

Heshmati H, Behnampour N, Khorasani F, Moghadam Z. Prevalence of chronic complications of diabete and its related factors in referred type 2 diabetes patients in Freydonkenar diabetes center. J Neyshabur Univ Med Sci. 2014;1(1):36–34.

21.

Bostani R, Afkhamizadeh M, Shahri B, Ahmadi S. Frequency of diabetic polyneuropathy based on clinical and phlebological findings. Med J Mashhad Univ Med Sci. 2012;55(2):81–7.

22.

Abbaspour S, Shamaeiyan N, Hasanzadeh M, Zandi Z, Sepehri A. Self-care behaviors among diabetic patients referred to a selected hospital clinic in Torbat-e-Heydarieh. Q Torbat Heydarieh Sch Med Sci. 2012;1(1):65–70.

23.

Azdanpanah P, Ghaffarian Shirazi HR, Hatamipour Y, Shariatinia F, Vafaei F. Prevalence of peripheral neuropathy in patients of type 2 diabetes mellitus in Dena township in 2004. J Armaghan-e-Danesh. 2005;11(1):75–81.

24.

Moosavi H, Tahery N, Rabii S, Rohani Manesh F. Prevalence of neuropathy in type II diabetic patients covered by the healthcare center of Ahwaz Petroleum Industry in 2012–2013. J Diabetes Nurs. 2014;2(3):29–37.

25.

Cabezas-Cerrato J. The prevalence of clinical diabetic polyneuropathy in Spain: a study in primary care and hospital clinic groups. Diabetologia. 1998;41:1263–9.CrossRef

26.

Bruce SG, Young TK. Prevalence and risk factors for neuropathy in a Canadian first nation community. Diabetes Care. 2008;31:1837–41.CrossRef

27.

Ashok S, Ramu M, Deepa R, Mohan V. Prevalence of neuropathy in type 2 diabetic patients attending a diabetes centre in South India. J Assoc Physicians India. 2002;50:546–50.PubMed

28.

Mimi O, Teng CL, Chia YC. The prevalence of diabetic peripheral neuropathy in an outpatient setting. Med J Malaysia. 2003;58:533–8.PubMed

29.

Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonsken PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36:150–4.CrossRef

30.

Franklin GM, Kahn LB, Baxter J, Marshall JA, Hamman RF. Sensory neuropathy in non-insulin-dependent diabetes mellitus: the San Luis Valley diabetes study. Am J Epidemiol. 1990;131:633–43.CrossRef

31.

Dyck PJ, Katz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817–24.CrossRef

32.

Nabavi NM, Ahmed A, Bril V, Orszag A, Ng E, Nwe P, et al. Diabetic neuropathy and axon reflex-mediated neurogenic vasodilatation in type 1 diabetes. PLoS One. 2012;7940:e34807.CrossRef

33.

Sung JY, Park SB, Liu YT, Kwai N, Arnold R, Krishnan AV, et al. Progressive axonal dysfunction precedes development of neuropathy in type 2 diabetes. Diabetes. 2012;61(6):1592–8.CrossRef

34.

Won JC, Kwon HS, Kim CH, Lee JH, Park TS, Ko KS, et al. Prevalence and clinical characteristics of diabetic peripheral neuropathy in hospital patients with type 2 diabetes in Korea. Diabet Med. 2012;29(9):e290–e6.CrossRef

35.

Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341–50.CrossRef

36.

Oguejiofor OC, Odenigbo CU, Oguejiofor CB. Evaluation of the effect of duration of diabetes mellitus on peripheral neuropathy using the United Kingdom screening test scoring system, bio-thesiometry and aesthesiometry. Niger J Clin Pract. 2010;13(3):240–7.PubMed

37.

Franse LV, Valk GD, Dekker JH, Heine RJ, van Eijk JTM. Numbness of the feet is a poor indicator for polyneuropathy in type 2 diabetic patients. Diabet Med. 2000;17:105–10.CrossRef

38.

American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2009;32(Suppl 1):S13–S61.CrossRef

Titel: Prevalence of neuropathy in patients with type 2 diabetes in Iran
A systematic review and meta-analysis
verfasst von: Dariush Afshari Aliabadi, MD
Nasrin Moradian, MD
Elham Rahmanian, MSc
Masoud Mohammadi, MSc
Publikationsdatum: 17.12.2020
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 5-6/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-020-01784-w

Springer Medizin Österreich

Summary

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5-6/2021

Multimethod assessing the prognosis affecting factors of hospitalized children with burns in Zunyi, southwest China

Silicone soft socket system for the treatment of geriatic transtibial amputees

Plateletcrit may not provide a distinction between patients with adult-onset Still’s disease and sepsis

A novel method of clinical first tarsometatarsal joint hypermobility testing and radiologic verification

Diagnosis of hepatic nuclear factor 1A monogenic diabetes mellitus (HNF1A-MODY) impacts antihyperglycemic treatment

Assessing the health-related quality of life in type 2 diabetes patients treated with insulin and oral antidiabetic agents